Last reviewed · How we verify

NCT03851198

Early Diagnosis of Patients With Mild Cognitive Impairment Through the Parameterization of Functional Tests.

Withdrawn NA Last updated 7 December 2023
What this trial tests

NA trial testing Standard Care or Usual Clinical Practice in Mild Cognitive Impairment. Withdrawn.

Timeline
1 April 2020
Primary endpoint
1 July 2021
1 September 2021

Quick facts

Lead sponsorUniversity of Malaga
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingdouble
Primary purposediagnostic
Start date1 April 2020
Primary completion1 July 2021
Estimated completion1 September 2021
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

University of Malaga

Who can join

60 and older, any sex, with Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study aims to develop an index formed by the variables, functional tests, scales and instruments that best discriminate between healthy subjects and subjects with MCI and that allows the stratification of different levels of severity of MCI, and to validate new systems for the early diagnosis of subjects with mild cognitive impairment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Standard Care or Usual Clinical Practice

Trials testing the same drug.

Other recruiting trials for Mild Cognitive Impairment

Currently open trials in the same condition.

Other University of Malaga trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03851198.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing